Updated August 2026
The Receipts Behind “No Pay-For-Placement”
GLP-1 Programs We Declined to Recommend — and Why
Every “best GLP-1 provider” list on the internet claims to be independent. Here’s our proof: the affiliate programs we walked away from, including ones that approved us and would have paid us. When a provider fails our published standard, we don’t link it — and when one clears our bar with flags on it, we print the flags next to the link.
How this works
Before we link to any provider, it has to clear our public vetting standard: a named pharmacy, a named licensed medical team, LegitScript certification, transparent pricing, and honest claims. Passing all five earns an unreserved recommendation. Clearing at least three, including the named-pharmacy and LegitScript checks, earns a conditional link, and we publish every flag on the review page itself, above the fold, before any button. Failing the pharmacy check, the certification check, or the pricing check is disqualifying no matter how the rest score. We screened roughly 49 GLP-1 affiliate programs on our network. As of August 2026, one program clears all five and one clears three of five with both of its flags published in full — our assessments are in the Embody GLP-1 review and the Bodybuilding Health+ review. This page covers the other side of that ledger.
To be clear about what “declined” means: these are programs we chose not to recommend based on our criteria and publicly available information at the time of review. It is not a claim that any of them is unlawful or unsafe, and if a provider later meets all five checks, we’ll say so.
Declined: telos rx (August 2026)
telos rx is a LegitScript-certified telehealth platform offering compounded semaglutide and tirzepatide, plus peptide, anti-aging, and sexual-health products. Its affiliate program approved us, generated a working commission link, and we declined to use it. Three of our five checks, based on publicly available information as of August 2026:
- Named pharmacy — not met. Its materials refer to “licensed US compounding pharmacies” without naming them. Our standard requires knowing exactly who compounds the medication, and we ask readers to walk away from any provider that won’t say.
- Named medical team — not met. The platform’s own terms describe it as a technology and administrative services company that does not provide medical services, connecting patients to a medical group it doesn’t name. We found no named chief medical officer to verify.
- Transparent pricing — not met. Independent press coverage documents a $49/month headline offer against real ongoing costs reported at $129–$449/month depending on plan and dose. A price you only learn after intake is the pattern our fourth check exists to catch.
What it did have: LegitScript certification and generally positive customer reviews. That’s not nothing — it’s just not enough to meet a standard we apply without exceptions. If telos rx publicly names its pharmacies and medical leadership and publishes its real ongoing pricing before intake, we’ll re-screen it.
The patterns behind the other declines
Most of the ~49 programs we screened failed the same few ways. If you’re evaluating a provider on your own, these are the patterns to watch for.
The anonymous pharmacy. By far the most common failure: “partnered with licensed US pharmacies,” no names. If the medication’s origin is a secret, so is its quality.
The invisible medical team. A “medical advisory board” with no names, or a corporate structure where the platform legally provides no medical care and won’t say who does. A real, checkable license behind every prescription is the minimum.
The teaser price. A large advertised number ($49, $79) that quietly becomes $200–$400 once you’re through intake. We treat the price you can find before signup as the only price that counts.
The equivalence claim. Marketing that presents compounded product as if it were the FDA-approved drug, or leans on formulation workarounds to sidestep regulatory limits. This is the pattern that drew FDA warning letters to 30 telehealth companies in February 2026.
The self-written review. “Independent” comparison articles published by the provider itself, ranking itself first. If the review and the product share an owner, it’s an ad.
Why we publish this
Affiliate money shapes most GLP-1 content you’ll read, and the shaping is invisible — you never see the programs a site joined and stayed quiet about, or the ones it promoted because the payout was better. We think the only honest answer is receipts: our standard is public, both linked partners are disclosed, flags included, and the programs we turned down are on this page. If we ever fail our own test, this page is where you’d catch us.